Aptamers and use of the aptamers in the diagnosis and treatment of cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent covers a new class of aptamers—small nucleic acid molecules—that specifically recognize and bind to solid tumor cancer cells but not to healthy cells or non-solid tumor cells. These aptamers can be used for both the diagnosis (as biomarkers or imaging agents) and targeted therapy of various solid tumors. Furthermore, these aptamers have the ability to enter tumor cells and can deliver therapeutic cargos such as siRNA or other anti-cancer agents directly into the cancer cells, enabling efficient and highly specific treatment with potentially lower side effects than conventional methods.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and accurate diagnosis of solid tumors through the detection of tumor cells in tissue or fluid samples (e.g., biopsies, blood, urine).
• Molecular imaging of tumors using aptamer-based probes in medical diagnostics such as fluorescence imaging or flow cytometry.
• Targeted delivery of therapeutic agents (e.g., small interfering RNA, antagomirs, toxins) directly into tumor cells, increasing efficacy and reducing off-target effects.
• Development of new anticancer drugs or combination therapies where aptamers carry more than one agent to circumvent drug resistance.
• First-line treatment of various solid tumors (e.g., breast, lung, pancreatic, cervical cancers), potentially replacing less specific chemotherapies.
• Creation of diagnostic test kits or devices that use aptamer technology for detecting cancer cells in clinical settings or laboratories.

BenefitsContent extracted from patent full text and abstract with AI.

• High specificity for cancer cells from solid tumors, minimizing impact on healthy cells and reducing side effects.
• Broad-spectrum recognition of different types of solid tumors, allowing a single formulation to target multiple cancers.
• Low toxicity and immunogenic response compared to antibody-based therapies, improving patient safety profile.
• Delivery of therapeutic cargoes like siRNA directly into tumor cells, enabling highly targeted gene-silencing or apoptosis-inducing treatments.
• Reduced cost and accelerated drug development due to modular design and broad-spectrum action of aptamers.
• Potential for combination therapies via aptamer-mediated multi-agent delivery, addressing drug resistance more effectively.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, a composition comprising an aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly solid tumours